Belgium's liver-focused stem cell therapy developer Promethera raises $44M+ in latest round
Betting on its stem cell therapy for end-stage liver disease, Belgium-based Promethera Biosciences has got €39.7 million (about $44.4 million) in the bank to develop the drug as an alternative to often hard-to-procure transplants.
Established in 2009, Promethera’s lead drug is an experimental stem cell therapy called HepaStem for patients with a deadly syndrome called acute-on-chronic liver failure, or ACLF, for whom transplants are the only existing rescue treatment. Derived from human livers, the therapy is formulated using mesenchymal stem cells (MSCs) replete with liver markers and liver features. At the International Liver Congress last month, Promethera presented data from an ongoing dose-escalation Phase IIa study, which showed the treatment is safe and suggested “trends in efficacy.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.